In this work, we presented a preliminary evaluation of the different enhancer-target interactions associated with anti–PD-1/PD-L1 immunotherapy across tumor types, and successfully identified potential enhancer-based biomarkers of risk and beneficial responses. This evidence concerns the gene PDCD1 and neoplasm.